Infectious Agents and Cancer · 2015 · 45 citations · 45 references
MedicineCancer BiologyOncologyEpigeneticsGene ExpressionMolecular OncologyCancer EpigeneticsCervical CancerCervical Intraepithelial NeoplasiaEpigenetic Alterations In CancerEpigenetic Regulation In CancerMalignant NeoplasmsDna Methylation ModulationEpigenetic Alterations In CarcinogenesisEpigenetic Silencing Of Tumor Suppressor GenesMalignant ProgressionMicrorna EpigeneticsMicrorna In CancerMicrorna Regulation In CancerTumor Suppressor Gene Methylation
BACKGROUND: The aberrant expression of miR-23b is involved in the development and progression of cancer. The aim of this study was to evaluate the potential role of methylation in the silencing of miR-23b in cervical cancer cell lines and to determine its expression in stages of malignant progression and in cervical cancer tissues HPV16-positive. METHODS: The methylation of the miR-23b promoter was determined in HeLa, SiHa, CaSki and C33A cells using a Human Cancer miRNA EpiTectMethyl II Signature PCR Array®. The cells were treated with 5-Aza-2'-deoxycytidine, and the expression of miR-23b, uPa, c-Met and Zeb1 was determined by qRT-PCR. miR-92a and GAPDH were used as controls. The expression of miR-23b was determined in cervical scrapes and biopsies of women without squamous intraepithelial lesions, with precursor lesions and with cervical cancer, all were HPV16-positive. The Fisher exact and Mann-Whitney tests were used to compare the differences of the expression of miR-23b, uPa, c-Met and Zeb1 among cell groups, and the difference among patients, respectively. The association between the expression of miR-23b and cervical cancer was determined by logistic regression with a confidence level of 95 %. A value of p < 0.05 was considered statistically significant. RESULTS: In C33A, HeLa and CaSki cells, methylation was associated with decreased expression of miR-23b. After treatment with 5-Aza-CdR, the expression of miR-23b increased in all cell lines and the expression of c-Met decreased in HeLa cells, while uPa and Zeb1 decreased in C33A and CaSki cells. In SiHa cells the expression of uPa, c-Met and Zeb1 increased. The expression of miR-23b decreased in relation to the increase in the severity of the lesion and was significantly lower in cervical cancer. In women with premalignant lesions HPV16-positive, decreased levels of miR-23b increased the risk of cervical cancer (OR = 36, 95 % CI = 6.7-192.6, p < 0.05). CONCLUSIONS: The results suggest that the expression of miR-23b is regulated by the methylation of its promoter and is possible that this microRNA influence the expression of uPa, c-Met and Zeb1 in cervical cancer cells lines. In women with premalignant lesions and cervical cancer infected with HPV16, the expression level of miR-23b agree with a tumor suppressor gene.
45
Drug delivery with carbon nanotubes for in vivo cancer treatment
Zhuang Liu, Kai Chen, Corrine R. Davis et al. · PubMed · 2008 · 2.3K citations · Full text
Pharmacy, Oncology, Pharmacology +17
Chromatin structure analyses identify miRNA promoters
Fatih Ozsolak, Laura L. Poling, Zhengxin Wang et al. · Genes & Development · 2008 · 666 citations · Full text